On 14 February 2019, Vaccibody AS (‘Vaccibody’ or the ‘Company’) announced the successful placement of 5,750,000 new shares in the Company at a subscription price of NOK 40 per share, raising gross proceeds of NOK 230m. The private placement received strong interest from existing shareholders and new investors. The net proceeds will i.a. be used to conduct a Phase IIa clinical study resulting from Vaccibody’s recently announced agreement with Roche, preparation of expansion cohorts in the Company’s cancer neoantigen programme and initiation of two such cohorts, as well as for general corporate purposes.
ABG Sundal Collier acted as Joint Bookrunner in the transaction.
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is currently enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of the head and neck. Vaccibody’s front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), which has reported positive 6M interim data, evaluates the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3).